Lifting the Mood on Treating Fragile X
Author(s)
Kind, Peter C.
Osterweil, Emily
Bear, Mark
Date Issued
November 2012
Journal
Biological Psychiatry
Publisher
Elsevier
Citation
Osterweil, Emily K., Peter C. Kind, and Mark F. Bear. “Lifting the Mood on Treating Fragile X.” Biological Psychiatry 72, no. 11 (December 2012): 895–97.
Version
Author's final manuscript
Abstract
Only a decade ago, it was believed that a genetic diagnosis of intellectual disability and autism offered little in the way of hope for a medical treatment to lessen the burden on the affected individuals and their families. However, recent research aimed at understanding the cellular and molecular mechanisms that underlie the pathogenesis of ASD has ushered in a new era of targeted treatment strategies. Studies in fragile X syndrome (FXS) have been at the forefront of this revolution, and they are forging a path that could define future approaches to the treatment of ASD.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.biopsych.2012.09.017
